Should I buy or sell Phathom Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHAT shares. View PHAT analyst ratings or view top-rated stocks .

What is Phathom Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12-month target prices for Phathom Pharmaceuticals' stock. Their PHAT share price targets range from $10.00 to $28.00. On average, they anticipate the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 125.0% from the stock's current price. View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts .

How have PHAT shares performed in 2024?

Phathom Pharmaceuticals' stock was trading at $9.13 on January 1st, 2024. Since then, PHAT stock has increased by 3.8% and is now trading at $9.48. View the best growth stocks for 2024 here .

When is Phathom Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PHAT earnings forecast .

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.12. The firm earned $0.68 million during the quarter, compared to analyst estimates of $0.93 million. During the same period in the prior year, the business earned ($1.33) earnings per share.

What ETFs hold Phathom Pharmaceuticals' stock?

ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS) , AbbVie (ABBV) , Algonquin Power & Utilities (AQN) , BCE (BCE) , Cinemark (CNK) , CenterPoint Energy (CNP) , Canadian Natural Resources (CNQ) , Brinker International (EAT) and Consolidated Edison (ED) .

When did Phathom Pharmaceuticals IPO?

Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (12.76%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi , David A Socks , Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran . View institutional ownership trends .

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PHAT Stock Alerts

$9.48

-0.32 (-3.27%)

(As of 04/18/2024 ET)

Compare

Today's Range: $9.45
▼
$9.82
50-Day Range: $6.21
▼
$12.05
52-Week Range: $6.07
▼
$17.02

Volume: 421,170 shs
Average Volume: 868,076 shs
Market Capitalization: $554.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.33

Get Phathom Pharmaceuticals alerts:

Phathom Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 125.0% Upside
$21.33 Price Target
Short Interest: Bearish
39.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 4 Articles This Week
Insider Trading: Selling Shares
$30.24 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.22) to ($3.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

Medical Sector

612th out of 918 stocks

Pharmaceutical Preparations Industry

280th out of 430 stocks

3.4

Analyst's Opinion

Consensus Rating
Phathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Phathom Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
39.95% of the float of Phathom Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.
Change versus previous month
Short interest in Phathom Pharmaceuticals has recently increased by 2.01%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Phathom Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Phathom Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHAT.

1.9

News and Social Media Coverage

News Sentiment
Phathom Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,240,515.00 in company stock.
Percentage Held by Insiders
27.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.22) to ($3.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phathom Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phathom Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHAT Stock News Headlines

April 11, 2024 | insidertrades.com

Molly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

March 27, 2024 | insidertrades.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 16,851 Shares

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 14, 2024 | americanbankingnews.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 3%

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)

April 12, 2024 | investing.com

Phathom Pharmaceuticals CFO sells over $38k in company stock

April 12, 2024 | americanbankingnews.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 3,435 Shares

April 12, 2024 | americanbankingnews.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.2% Following Insider Selling

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | markets.businessinsider.com

Buy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising Pipeline

April 9, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)

April 7, 2024 | msn.com

Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst

April 6, 2024 | markets.businessinsider.com

Optimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data Fluctuations

April 5, 2024 | finance.yahoo.com

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

April 3, 2024 | finance.yahoo.com

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 3, 2024 | globenewswire.com

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)

March 28, 2024 | stockhouse.com

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"

March 28, 2024 | investing.com

Phathom Pharmaceuticals CEO sells shares worth over $153,000

March 26, 2024 | finance.yahoo.com

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

March 25, 2024 | finance.yahoo.com

SIGA Names Larry Miller General Counsel

March 23, 2024 | markets.businessinsider.com

Positive Prescription Trends and Resilience Prompt Buy Rating for Phathom Pharmaceuticals

March 18, 2024 | seekingalpha.com

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

March 16, 2024 | finance.yahoo.com

PHAT Apr 2024 10.000 call

March 9, 2024 | seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

March 9, 2024 | markets.businessinsider.com

Maintaining Neutral on Phathom Pharmaceuticals Amid Voquezna Launch Uncertainties

March 8, 2024 | finance.yahoo.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript

See More Headlines

Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PHAT
CUSIP: N/A
CIK: 1783183
Web: www.phathompharma.com
Phone: 877-742-8466
Fax: N/A
Employees: 452
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.33
High Stock Price Target: $28.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +125.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-201,590,000.00
Net Margins: N/A
Pretax Margin: -29,558.95%
Return on Equity: N/A
Return on Assets: -63.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.25
Quick Ratio: 10.22

Sales & Book Value

Annual Sales: $680,000.00
Price / Sales: 815.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.27) per share
Price / Book: -7.46

Miscellaneous

Outstanding Shares: 58,520,000
Free Float: 42,664,000
Market Cap: $554.77 million
Optionable: Optionable
Beta: 0.63

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Terrie J. Curran (Age 55)
President, CEO & Director
Comp: $1.11M
Mr. David A. Socks (Age 49)
Co-Founder & Director
Comp: $58.78k
Dr. Azmi Nabulsi M.D. (Age 65)
M.P.H., Co-Founder & COO
Comp: $815.21k
Ms. Molly Henderson CPA (Age 53)
MBA, Chief Financial & Business Officer
Comp: $671.27k
Dr. Aditya Kohli Ph.D. (Age 35)
Co-Founder
Comp: $319.65k
Mr. Lawrence R. Miller Esq.
J.D., General Counsel & Secretary
Mr. Tom Harris
Chief Development Sciences Officer
Dr. Eckhard Leifke M.D.
Ph.D., Chief Medical Officer
Mr. Martin J. Gilligan
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PHAT Stock Analysis - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHAT shares.
View PHAT analyst ratings or view top-rated stocks.
What is Phathom Pharmaceuticals' stock price target for 2024?: 4 analysts have issued 12-month target prices for Phathom Pharmaceuticals' stock. Their PHAT share price targets range from $10.00 to $28.00. On average, they anticipate the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 125.0% from the stock's current price.
View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts.
How have PHAT shares performed in 2024?: Phathom Pharmaceuticals' stock was trading at $9.13 on January 1st, 2024. Since then, PHAT stock has increased by 3.8% and is now trading at $9.48.
View the best growth stocks for 2024 here.
When is Phathom Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PHAT earnings forecast.
How were Phathom Pharmaceuticals' earnings last quarter?: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.12. The firm earned $0.68 million during the quarter, compared to analyst estimates of $0.93 million. During the same period in the prior year, the business earned ($1.33) earnings per share.
What ETFs hold Phathom Pharmaceuticals' stock?: ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).
When did Phathom Pharmaceuticals IPO?: Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.
Who are Phathom Pharmaceuticals' major shareholders?: Phathom Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (12.76%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran.
View institutional ownership trends.
How do I buy shares of Phathom Pharmaceuticals?: Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Phathom Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

PHAT Stock Price History

PHAT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PHAT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™